Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: olsson t. Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Mult Scler. 2018. PMID: 29353550
Immunological patterns identifying disease course and evolution in multiple sclerosis patients.
Furlan R, Rovaris M, Martinelli Boneschi F, Khademi M, Bergami A, Gironi M, Deleidi M, Agosta F, Franciotta D, Scarpini E, Uccelli A, Zaffaroni M, Kurne A, Comi G, Olsson T, Filippi M, Martino G. Furlan R, et al. Among authors: olsson t. J Neuroimmunol. 2005 Aug;165(1-2):192-200. doi: 10.1016/j.jneuroim.2005.04.012. J Neuroimmunol. 2005. PMID: 15949850
A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis.
Jagodic M, Colacios C, Nohra R, Dejean AS, Beyeen AD, Khademi M, Casemayou A, Lamouroux L, Duthoit C, Papapietro O, Sjöholm L, Bernard I, Lagrange D, Dahlman I, Lundmark F, Oturai AB, Soendergaard HB, Kemppinen A, Saarela J, Tienari PJ, Harbo HF, Spurkland A, Ramagopalan SV, Sadovnick DA, Ebers GC, Seddighzadeh M, Klareskog L, Alfredsson L, Padyukov L, Hillert J, Clanet M, Edan G, Fontaine B, Fournié GJ, Kockum I, Saoudi A, Olsson T. Jagodic M, et al. Among authors: olsson t. Sci Transl Med. 2009 Dec 9;1(10):10ra21. doi: 10.1126/scitranslmed.3000278. Sci Transl Med. 2009. PMID: 20368159
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Berger JR, et al. Among authors: olsson t. Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083. Ann Neurol. 2010. PMID: 20818795 No abstract available.
Principles of a new treatment algorithm in multiple sclerosis.
Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Hartung HP, et al. Among authors: olsson t. Expert Rev Neurother. 2011 Mar;11(3):351-62. doi: 10.1586/ern.11.15. Expert Rev Neurother. 2011. PMID: 21375441 Review.
1,227 results